About this trial
Telemedicine has developed rapidly during the COVID-19 pandemic and is now integrated into the clinical practice of many hospitals. Telemedicine offers many advantages, and even after the end of the pandemic, many patients still choose to undergo healthcare visits remotely. However, the rapid expansion of telemedicine may be associated with the risk of providing patients with unvalidated and uncontrolled telehealth solutions, potentially negatively impacting their health.
In this study, the researchers aim to investigate the effectiveness of remote cognitive training in patients with mild-to-moderate Alzheimer's disease (AD) using tablets equipped with virtual reality-based cognitive exercises. The investigators also aim to evaluate the impact of online supervision of cognitive training by a neuropsychologist and to compare the costs and burden of home-based versus hospital-based cognitive training in patients with AD. This project will define the optimal modalities for cognitive telerehabilitation to ensure validated protocols for the continuity of care in AD.
Eligibility criteria
Qualifiers
Age between 50 and 90 years.
Diagnosis of Alzheimer's disease according to established diagnostic criteria.
Mini-Mental State Examination (MMSE) score between 18 and 24.
Stable pharmacological treatment for at least 3 months before enrolment.
Disqualifiers
Refusal or inability to provide written informed consent.
History of psychiatric disorders.
Significant cerebrovascular disease.
Severe visual or hearing impairment that could interfere with study procedures.
Trial design
Treatments tested in this trial
- Online cognitive telerehabilitation
- VRRS tablet